|
|
Blood, Vol. 113, Issue 18, 4341-4351, April 30, 2009
CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy
Blood Azab et al.
113: 4341
Supplemental materials for: Azab et al
Files in this Data Supplement:
- Figure S1 (JPG, 90.1 KB)
-
MM.1S treated with AMD3100 (50µM), bortezomib (5 nM) or the combination for 24 hrs, and expression of VLA4 (A) and ICAM (B) was tested by flow cytometry compared to non treated cells, and none of the treatments altered the expression of VLA4 or ICAM. (C) AMD3100 effect on tumor reduction induced by low dose of bortezomib in vivo. Mice were treated with AMD3100 (5mg/kg, daily), bortezomib (0.25 mg/ml, twice a week) or their combination, and compared control untreated group. Tumor growth was determined by bioluminescence imaging. Tumor growth in the AMD3100 treated group was similar to the control group, while the bortezomib treated group showed reduction in tumor progression compared to control (p=0.025), and the mice treated with combination of combination AMD3100 and bortezomib demonstrated significant tumor reduction, compared to the control (p=0.029), while it was not statistically significant compared to bortezomib alone (p=0.481). Each data point represents 3–5 mice.
|
|
